Aptamer Group plc reported a strong trading update for the year ended 30 June 2026, with expected revenue of approximately £1.5 million, a 25% year-on-year increase, driven by fee-for-service programmes and initial licensing revenues from agreements with Twist Bioscience and Alphazyme. The company's sales pipeline grew 55% to £4.8 million, with an FY2027 order book of £0.6 million, indicating enhanced future revenue visibility. Aptamer also generated its first licensing revenues, a key milestone in its higher-margin strategy, and continues to invest in its AI-enabled discovery platform and internal therapeutic pipeline. The company remains well-funded following an April 2026 fundraise, with cash runway extending into at least 2028.
